Alshifa Hospital-perinthalmanna

 Alshifa Hospital- Perinthalmanna, Kerala

Malappuram, a district in the state of kerala is known for its rich cultural and political heritage. It’s a land abounding in hills, valleys, plantations, rivers, waterfalls, and beautiful beaches. The district is also well known as the major healthcare destination in south Malabar. Perintalmanna, also known as ‘hospital town of  Malappuram’ has four privately-owned multi-super specialty hospitals.

Alshifa hospital Pvt.Ltd is a multispecialty hospital established in 1989 as a NRI venture having 450 beds, over 30 disciplines of various specialties and super specialties with more than 60 consultants of National reputation. The Hospital is renowned for its highly skilled and experienced medical professionals and provides excellent treatment services to patients all over the world. People from all walks of life including neighbouring states and gulf countries walk into Alshifa for their better health. Alshifa has created a niche and revolution in Malabar region of  kerala by taking care of health of thousands of people irrespective of their socio economic back ground. With skilled professionals, unmatched expertise, world class treatment, cost effective prices, combined with health tourism which includes complete health checkup, posh villas to reside, Alshifa has emerged as a favourite destination for medical tourism in the Malabar region of Kerala. Every year, hundreds of thousands of patients from all over the Middle East and many other foreign countries come here to make use of our modern treatment facilities.

Expansion work in any healthcare institution is always never-ending. We are on the journey of expansion in order to meet the increasing demand from the patient and families for more beds. Now that there is a need for one more building, construction  of 10floor spacious building is going on with the latest infrastructure which is scheduled for inauguration on January 2014. With the successful completion of this project, it will be a dream come true and proud moment for the whole team of Alshifa under the Dynamic leader ship of Mr P Unneen, Managing trustee, Alshifa group

Dilip.C

Associate Professor/Editor in Chief( Shifa clinpharm News letter)

Alshifa college of pharmacy

Perinthalmanna

An another Golden feather to the victorious hat of Al shifa college of pharmacy

An another Golden feather to the victorious hat of Al shifa college of pharmacy

We, the students of M pharm (Dept of Pharmacy practice), Al shifa college of pharmacy are extremely delighted to share the overwhelming triumph achieved by our batchmate, Ajmal.M, who was being honoured with the 1^st prize for scientific poster presentation in a national seminar titled  “ Pharmacon IV ” held at Nehru college of pharmacy campus on November 16^th and 17^th. The program being inaugurated by Dr. P. Krishnakumar, Patron and presided by Dr. K. Raghavan nambiar, Chairperson was highlighted by Dr. K. Gopalan, Dr. Venkata rao and Dr. P. Solayaraj who had delivered speeches on the various aspects of emerging innovative dynamics in the field of pharmaceutical profession and research. The second day witnessed the scientific poster presentation competition with about 100 posters being showcased representing various pharmacy colleges in South India. Hoping this history of notch up would repeat in the coming years too.

Vinod.B

Shanoob.K

VACCINE STORAGE WITH OUT REFRIGERATION

VACCINE STORAGE WITH OUT REFRIGERATION

Keeping medications cold from production until they are used in treatment is a costly process, accounting for as much as 80 percent of the price of vaccinations. The need for a cold chain has been a difficult for health care providers, aid organizations, scientists and pharmaceutical companies for decades, especially in settings where electricity is limited. Failures in the chain result in the loss of nearly half of all global vaccines

In an attempt to solve this problem, the scientists developed silk films that essentially wrap up the live bioactive molecules present in antibiotics and vaccines. This protects these essential bioactive elements, and so can greatly extend the shelf-life of the medication. The active drugs are released as the silk film is slowly degraded by enzymes in the body.The vaccines like measles, mumps, rubella and antibiotics like penicillin, tetracycline sect are tested using this method, and in all cases the silk film encapsulated medications remained potent far longer at elevated temperature. These advances could reduce the cost of vaccination programme.

COLOUR TESTS TO SPOT EARLY HIV AND PROSTATE CANCER

COLOUR TESTS TO SPOT EARLY HIV AND PROSTATE CANCER

Researchers in the UK have developed a "naked eye" colour test for virus and disease biomarkers which is ten times more sensitive than current gold standard methods. They have tested it on HIV and prostate cancer biomarkers, and suggest it offers a cheap and simple way of spotting early onset of these diseases.

The detection is done by analyzing serum, derived from blood, in a disposable, see-through container. If the result is positive for p24 or PSA, the solution inside the container turns blue, if it is negative, it turns red. The enzyme label of an enzyme-linked immunosorbent assay (ELISA) controls the growth of gold nanoparticles and generates coloured solutions when the analyte (eg p24 or PSA) is present. If the analyte is present, the reaction generates irregular clumps of nanoparticles, and these give off a distinct blue colour in the solution inside the container. If the analyte is absent, the nanoparticles separate into ball-like shapes, which give off a reddish colour. The reactions can be seen with the naked eye.

This may help testing patients on HIV treatment to assess the effectiveness of retroviral therapies and also to check for new infections, with less expense and also to detect early signs of cancer.

Linu Mohan

Asst prof

FDA APPROVES ARTIFICIAL CERVICAL DISC-:

FDA APPROVES ARTIFICIAL CERVICAL DISC-:

Globus Medical Company developed a new medical device SECURE®-C, got approval from FDA. It is an artificial cervical disc consisting of two metal (cobalt-chrome alloy) endplates and a plastic (polyethylene) insert that fits between the endplates. The device can be used in skeletally mature patients with diseased cervical disc, or following removal of the disc for conditions that result from a diseased or bulging disc (intractable radiculopathy or myelopathy). The device is placed between two adjacent neck bones (vertebrae) to replace a cervical disc. The implanted device is designed to restore the distance between the two vertebrae and allow motion at the treated level as the plastic core moves against the metal endplates.                                      

The device helps to stabilize the operated disc in the neck and improves the function. It should not be used in patients with infection, osteoporosis, allergy to metal or plastic used in the device, with unstable cervical spine, and patients with more than one cervical disc to be treated etc.

Linu mohan

Asst prof